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Objective: To estimate the cost-effectiveness of fluticasone propionate–salmeterol combination 
(FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary 
disease (COPD).
Study design: Pooled economic analysis.
Methods: We performed an economic analysis of pooled data from two randomized clinical 
trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 µg 
twice daily) or salmeterol (50 µg twice daily) on exacerbation rates in patients with severe 
COPD. We calculated exacerbation rates and applied standardized costs to exacerbation-related 
health care utilization reported in the trials (office, urgent care, and emergency department visits; 
hospitalizations; and oral corticosteroids and antibiotics) to determine cost differences between 
FSC and salmeterol treatment outcomes.
Results: Annual rates of any exacerbation and moderate/severe exacerbation were lower in 
the FSC group than the salmeterol group (4.91 vs 5.78 and 1.32 vs 2.00 respectively, both 
P , 0.05). Total adjusted annual COPD related exacerbation and therapeutic costs were 
$4,842 (95% CI; $4,731–$4,952) in the FSC group and $5,066 (95% CI; $4,937–$5,195) in 
the salmeterol group.
Conclusions: FSC combination therapy is associated with reduced risk of any exacerbation 
and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs 
compared to treatment with salmeterol. This analysis demonstrates that FSC therapy may be 
advantageous from both a clinical and cost-benefit standpoint for patients with severe COPD.
Keywords: COPD, cost-effectiveness analysis, economic, maintenance therapy
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airway obstruction 
and inflammation that leads to chronic bronchitis and emphysema. It affects 
approximately 210 million people worldwide and leads to 3 million deaths annually.1 
In the United States, COPD affects 24 million adults and accounts for 8 million 
physician visits, 1.5 million emergency department (ED) visits, 726,000 hospitaliza-
tions, and 119,000 deaths annually.2,3 The US economic burden of COPD in 2007 was 
$42.6 billion, including $26.7 billion in direct health care expenditures.4
Exacerbations are a primary concern in the clinical management of COPD and are 
associated with accelerated lung function decline, hospitalization or treatment in the 
ED, and an overall negative impact on quality of life.5–7 Clinical studies suggest that 
fluticasone propionate–salmeterol combination (FSC) therapy for COPD has clinical 
efficacy benefits over salmeterol monotherapy, including lower rates of exacerbation International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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and a reduced rate of decline in lung function;5,8–14 other 
observational studies have found that FSC is more cost-
effective than other therapies.15–17 However, no direct cost 
comparisons of FSC and salmeterol have been made using 
exacerbation and health care event data from randomized 
controlled trials (RCTs), making it difficult to evaluate the 
cost-benefit of these therapies or make formulary decisions 
based on willingness-to-pay (WTP) thresholds.
The objective of this study was to estimate the cost-
effectiveness of FSC compared to salmeterol for maintenance 
therapy in patients with severe COPD using data pooled from 
two RCTs that compared the effects of FSC and salmeterol 
on the annual rate of moderate/severe exacerbations in 
populations of severe COPD patients. Pooling data from 
trials is advantageous, particularly when the studies have 
similar protocols and patient-level data are available.18 This 
approach reduces the likelihood of false negative results, 
aids exploration of heterogeneity across studies, and helps 
resolve conflicting findings. To our knowledge, this is the 
first economic analysis to use clinical trial efficacy data 
associated with FSC and salmeterol therapy to estimate cost 
differences in COPD maintenance therapy following 1 year 
of treatment.
Methods
Overview
We performed a post hoc economic evaluation using pooled 
data from two recent RCTs to assess the cost-effectiveness 
of FSC compared to salmeterol for COPD management. The 
data were from two double-blind, parallel-group trials (Glaxo-
SmithKline SCO40043 and SCO100250) in which patients 
with COPD were randomized to receive FSC 250/50 µg 
twice daily or salmeterol 50 µg via Diskus™ dry powder 
inhaler, twice daily for 52 weeks. The study methods have 
been described previously.8,10 Patients were aged 40-years-old 
and older, had a cigarette smoking history of 10 pack-years 
or greater, a forced expiratory volume (FEV1) of 50% of 
predicted normal value or less, and a history of one or more 
exacerbations in the prior year that required treatment with 
oral corticosteroids, antibiotics, or hospitalization. Patients 
with asthma, other significant lung disease, and certain 
other significant and uncontrolled disorders were excluded. 
Concurrent use of inhaled long-acting bronchodilators, iprat-
ropium–albuterol combination products, inhaled corticoster-
oids and theophylline were not allowed, but albuterol could 
be used as needed. The planned study enrollment (N = 740 
per trial) provided 90% power to detect a greater than 20% 
reduction in the rate of   moderate/severe exacerbations in 
the FSC group compared to the salmeterol group at the 
95% level of significance based on estimated exacerbation 
rates of 1.5 for FSC and 1.9 for salmeterol. The first trial 
(SCO40043, N = 776) included 391 patients in the FSC group 
and 385 patients in the salmeterol group, and the second trial 
(SCO100250, N = 778) included 385 patients in the FSC 
group and 393 patients in the salmeterol group; all patients 
were included in our analysis.
The primary outcome measure of the trials was the annual 
rate of moderate/severe COPD exacerbation. Secondary 
outcomes were time to first moderate/severe COPD exacer-
bation, annual rate of moderate/severe COPD exacerbation 
requiring treatment with oral corticosteroids, and pre-dose 
AM FEV1. Individually, the trials reported similar results, 
including an approximately 30% lower annual rate of 
exacerbations in the FSC group than the salmeterol group 
(P , 0.001).8,10 Secondary outcomes also favored FSC ther-
apy over salmeterol. Adverse event profiles of the groups were 
similar with the exception of a higher incidence of known 
local inhaled corticosteroids (ICS)-related side effects (can-
didiasis and dysphonia) and pneumonia in the FSC group, 
although percentages of study subjects experiencing these 
effects in the clinical trials were very low. The percentage of 
patients experiencing candidiasis in the FSC group was 4% in 
SCO40043 compared to 2% in the salmeterol group, and in 
SCO100250 it was 6% compared to ,1%; for dysphonia the 
percentages were 4% compared to ,1% in SCO40043 and 
5% compared to 1% in SCO100250. Percentages of patients 
having pneumonia were 7% in the FSC group compared to 
4% in the salmeterol group in SCO40043 and 7% compared 
to 2% in SCO100250.
In the clinical trials, a COPD exacerbation was defined 
as a worsening of two or more major symptoms (dyspnea, 
sputum purulence, and sputum volume) and one minor 
symptom (cough/wheeze, fever, sore throat, and cold). 
A moderate/severe exacerbation was defined as worsening 
symptoms requiring treatment with oral corticosteroids, 
antibiotics, or hospitalization, and a mild exacerbation was 
one that did not require these interventions. For our economic 
analysis, we evaluated moderate and severe exacerbations 
together as well as separately. A moderate exacerbation 
was defined as worsening symptoms that required an office, 
urgent care, (UC) or ED visit, and treatment with oral 
corticosteroids or antibiotics. A severe exacerbation was 
defined as worsening symptoms that required hospitalization. 
Exacerbation categories were not mutually exclusive; a 
patient could have one or more types of exacerbation. The 
exacerbation counts, level of severity, and related health care International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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events used in this analysis were based on the clinical trial 
investigator reports.
Costing methods
The costs assigned to exacerbation-related health care 
are shown in Table 1. The studies were not designed with 
the intention of performing economic analyses and there-
fore we were unable to utilize actual costs incurred in man-
aging and treating COPD. Instead we approximated costs 
using estimates obtained through prior research. While 
information was gathered in the clinical trials concerning 
exacerbation recovery time (length of hospital stay and 
length of oral corticosteroid and antibiotic treatments), 
the distributions for recovery times showed tremendous 
variation, with the potential for outliers to severely bias 
comparison results. In associating costs with exacerbation 
events, we have associated estimated costs for average 
length experiences.
COPD-related hospitalizations and ED visits have been 
used in prior studies as evidence of an exacerbation, and 
were the primary endpoints of the clinical trials used in 
this analysis.8,10 Costs for COPD-related hospitalizations 
and ED visits were derived from a study by Stanford et al.7 
Assigned costs for hospitalizations assume an average 
length of stay. Stanford et al found that COPD patients 
admitted to the hospital from the ED had an average length 
of stay of 5 days, or 8.4 days if ICU care was required. We 
also calculated the costs of exacerbation-related office and 
UC visits using costs derived from a study by Nurmagam-
betov et al.19
Costs of study drugs (FSC and salmeterol) and courses of 
oral corticosteroids and antibiotics to treat exacerbations were 
derived from the 2007 Wholesale Acquisition Cost (WAC) in 
the Drug Topics Red Book®.20 To assign an average cost to a 
course of antibiotic or oral corticosteroid therapy, the number 
of drug therapy events that occurred during the trials and the 
associated drug costs were summed, and a weighted average 
daily cost for each treatment was calculated. Antibiotic 
treatment of an exacerbation was assumed to require a 7-day 
regimen and oral corticosteroid treatment a 10-day regimen, 
regardless of the days of antibiotic or oral corticosteroid use 
captured in the trial reports. The costs were thus calculated 
to be $113.72 for an antibiotic course and $2.77 for an oral 
corticosteroid course.
Information on concomitant COPD and non-COPD 
medication utilization by study participants was available at 
a summary level by therapy group for each study. However, 
information was only available for the number and percentage 
of participants having any use of specific medications. For 
example, in SCO40043 76% of the FSC patients and 86% of 
the salmeterol patients had some use of COPD concomitant 
medications, and 96% of FSC patients and 95% of salmeterol 
patients had some use of non-COPD concomitant medications. 
However, it was unknown which individuals used specific 
medications and in what quantity. Because of the varying 
lengths of time patients were followed in the clinical 
trials and because the focus of our analysis is on exacerbation 
costs and therapeutic costs, we chose not to include cost 
estimates for concomitant medications in our analysis.
statistical analysis
The statistical analyses included descriptive, bivariate, and 
multivariate analyses. Frequencies for categorical variables 
and measures of central tendencies for linear data were 
calculated for patient characteristics, exacerbation events, 
exacerbation-related health care utilization, and associated 
health care costs.
Annual rates were calculated for any and moderate/
severe exacerbation events and Wilcoxon rank sum tests 
were performed to assess differences between treatment 
groups. Mean annualized rates of any and moderate/severe 
exacerbations by treatment group were also calculated using a 
generalized linear model with a negative binomial distribution 
and log link, controlling for treatment, investigator, COPD 
reversibility stratum (based on FEV1 response to albuterol 
at baseline screening), baseline disease severity, and time on 
treatment. In addition, mean annual rates for exacerbation-
related health care utilization (office, UC and ED visits, 
hospitalizations, and pharmacy) were estimated using similar 
negative binomial models. Relative risks for the FSC treatment 
group were calculated using model β coefficients.
Table 1 Unit costs used in the calculation of exacerbation costs
Input Cost in US dollars
Moderate exacerbation
  Office visit 96.00a,b
  Urgent care visit 96.00a,b
  emergency department visit 656.00a,c
  Antibiotic course, 7-day regimen 113.71d
  Corticosteroid course, 10-day regimen 2.77d
severe exacerbation
  standard hospitalization 6890.93a,c 
  Intensive care unit admission 12,375.41a,c
Treatment drug costs
    Fluticasone/salmeterol 250/50 µg twice daily,  
30-day supply
164.64d
  salmeterol 50 µg twice daily, 30-day supply 109.16d
Notes: aCosts were inflated to 2007 dollars using the Consumer Price Index.
bnurmagambetov et al.19 cstanford et al.7 d2007 Drug Topic redbook Annual.20International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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All patients in the study incurred pharmacy costs; not 
all patients incurred costs associated with medical care. 
In multivariate analyses, predicted values for annual total 
medical costs were calculated using the generalized linear 
model described above, but with a gamma distribution. 
For the predicted values, bootstrapped confidence intervals 
were calculated for the difference between means using the 
percentile method with 1000 samples. All analyses were con-
ducted with SAS version 9.1.3 for Windows (SAS Institute, 
Cary, NC).
Results
Patient characteristics
Baseline characteristics of patients in the pooled FSC and 
salmeterol groups are shown in Table 2. Randomization 
to treatment groups within the individual clinical trials 
successfully balanced the observable covariates, and this 
carried over to the pooled groups. Both the pooled FSC 
and salmeterol groups had a mean age of 65 years, were 
55% male, and had a mean duration of diagnosed COPD of 
approximately 8 years. Patients were also similar in terms 
of race, geographic region, body mass index, smoking 
status, pack-year history, COPD type (emphysema, chronic 
bronchitis, or both), and lung function.
exacerbation rates  
and costs, unadjusted
Unadjusted exacerbation rates are presented in Table 3. 
A small percentage of patients in both groups, approximately 
13%, had no exacerbations during the 52-week clinical 
trials. The percentage of patients in the FSC group who 
had a moderate/severe exacerbation was lower in the FSC 
group than the salmeterol group (53.9% vs 59.5%). The 
FSC group had a slightly higher percentage of patients with 
one to three (43.7% vs 42.8%) and four to six exacerbations 
(21.3% vs 20.7%), and a slightly lower percentage with seven 
to nine exacerbations (13.5% vs 15.7%). More than 8% of 
patients in each group had ten or more exacerbations. The 
cumulative effect was significantly lower annualized rates 
of any exacerbation (4.91 vs 5.78, P , 0.05) and moderate/
severe exacerbation (1.32 vs 2.00, P , 0.05) in the FSC 
group. On average, patients in the FSC group had more 
days on treatment than patients in the salmeterol group 
(305.0 vs 274.4).
Unadjusted patient costs are presented in Table 4. While 
mean total costs of the FSC group, unadjusted for differing 
number of days on treatment, were $465 higher than costs in 
the salmeterol group ($2778 vs $2313, P , 0.05), the FSC 
group’s unadjusted mean annualized total costs were $304 
lower ($4,291 vs $4,596, P , 0.05), or 93% of the salmeterol 
group’s costs.
exacerbation rates  
and costs, adjusted
Mean adjusted annual rates for exacerbation events for each 
treatment group are shown in Table 5. The adjusted rates 
for any exacerbation and moderate/severe exacerbation are 
slightly lower than the unadjusted rates shown in Table 3. 
The adjusted annual rate of any exacerbation was 4.76 in the 
FSC group and 5.67 in the salmeterol group (P , 0.001); 
the adjusted annual rate of moderate/severe exacerbations 
was 1.10 in the FSC group and 1.58 in the salmeterol group 
(P , 0.001). Compared to salmeterol therapy, the relative 
risk for FSC therapy is 0.84 for any exacerbation and 0.70 
for moderate/severe exacerbation (both P , 0.001). FSC 
Table  2  Patient  characteristics  in  the  pooled  clinical  trials 
sample
FSC group 
(N = 776)
SAL group 
(N = 778)
Clinical trial sCO40043 391 (50.4) 385 (49.5)
Clinical trial sCO100250 385 (49.6) 393 (50.5)
Age, mean (sD) 65.1 (9.1) 65.1 (9.0)
Male, mean (sD) 424 (54.6) 424 (54.5)
race, n (%)
  Black 33 (4.3) 40 (5.1)
  Caucasian 728 (93.8) 729 (93.7)
  Other 15 (1.9) 9 (1.2)
Body mass index, mean (sD) 27.5 (6.2) 27.4 (7.0)
smoking status, n (%)
  Current smoker 320 (41.3)a 317 (40.7) 
  Former smoker 455 (58.7)a 461 (59.3) 
Pack-years, mean (sD) 58.1 (31.8) 55.3 (26.7)
COPD duration, mean (sD) 8.2 (7.6) 8.1 (7.4)
COPD type, n (%)
  Chronic bronchitis 219 (28.2) 242 (31.1)
  emphysema 360 (46.4) 333 (42.9)a
  Both  197 (25.4) 202 (26.0)
FeV1% predicted, mean (sD) 33.4 (10.8) 33.3 (10.3)
FeV1/FVC, mean (sD) 0.45 (0.1) 0.45 (0.1)
region, n (%)
  Canada 93 (12.0) 94 (12.1)
  Mid-Atlantic 147 (18.9) 136 (17.5)
  Midwest 96 (12.4) 91 (11.7)
  north 82 (10.6) 80 (10.3)
  northeast 96 (12.4) 93 (12.0)
  south 69 (8.9) 78 (10.0)
  southeast 98 (12.6) 101 (13.0)
  West 95 (12.2) 105 (13.5)
Notes: aData missing for one patient; denominator is one less than total sample n
Abbreviations: FSC, fluticasone propionate/salmeterol 250 µg/50 µg; sAL, salme-
terol 50 µg; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory 
volume; FVC, forced vital capacity.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
183
Cost-effectiveness of FsC versus salmeterol in severe COPD patients
therapy was also associated with lower relative risk for most 
components of exacerbation-related health care costs, with 
the exception of ED/UC visits (P = 0.080).
The percentages of patients using specific components 
of exacerbation-related health care are shown in Table 6. 
There was a significant difference between groups in use 
of total medical services (44.1% of FSC group vs 50.3% of 
salmeterol group, P , 0.05), but not for subcomponents of 
medical services. Mean predicted adjusted annual health care 
costs for COPD-related exacerbation events are shown in 
Table 7. Estimated annual total exacerbation and therapeutic 
costs were $4,842 (CI $4,731–$4,952) for the FSC group and 
$5,066 (CI $4,937–$5,195) for the salmeterol group. These 
adjusted cost estimates, while slightly different in absolute 
Table 3 Exacerbations (unadjusted) in patients receiving fluticasone propionate/salmeterol versus salmeterol therapy
FSC group 
(N = 776)a,b
SAL group 
(N = 778)a,b
Patients with any exacerbation (mild, moderate, severe) 678 (87.4) 681 (87.5)
Patients with a moderate exacerbation 418 (53.9) 463 (59.5)
Patients with severe exacerbation 83 (10.7) 99 (12.7)
Patients with moderate/severe exacerbation 419 (54.0) 464 (59.6)
  Treated with antibiotic 378 (48.7) 402 (51.7)
  Treated with oral corticosteroid 311 (40.1) 363 (46.7)
  Treated with hospitalization 83 (10.7) 99 (12.7)
Annual rate of any exacerbation per 100 patients, mean (sD) 4.91 (4.11)  5.78 (4.43)c
Annual rate of moderate/severe exacerbation per 100 patients, mean (sD) 1.32 (2.05)  2.00 (2.95)c
Days on treatment, mean (sD) 305.0 (110.6) 274.4 (132.7)
number of exacerbations
  Patients with 0 exacerbations 98 (12.6) 97 (12.5)
  Patients with 1–3 exacerbations 339 (43.7) 333 (42.8)
  Patients with 4–6 exacerbations 165 (21.3) 161 (20.7)
  Patients with 7–9 exacerbations 105 (13.5) 122 (15.7)
  Patients with $10 exacerbations 69 (8.9) 65 (8.4)
Notes: aexacerbation events and days on treatment are derived from data reported to Us Food and Drug Administration in glaxosmithKline-sponsored clinical trials 
sCO40043 and sCO100250.8,10 exacerbation categories are not mutually exclusive. bFigures provided are n (%) unless otherwise indicated. cP , 0.05 for difference between 
rates, Wilcoxon rank sum test.
Abbreviations: FSC, fluticasone propionate/salmeterol 250 µg/50 µg; sAL, salmeterol 50 µg.
Table 4 Unadjusted healthcare costs associated with COPD exacerbations in patients treated with fluticasone propionate/salmeterol 
versus salmeterol: pooled clinical trials data
Cost component Cost in US dollars
FSC group, mean/median (SD)  
(N = 776)
SAL group, mean/median (SD) 
(N = 778)
Mean cost difference 
(FSC–SAL)
exacerbation-related costs
Total cost, any exacerbation  
(mild, moderate, severe)
1127/114 (2906) 1351/116 (3225) -224a
Total cost, moderate exacerbation  243/114 (352) 301/116 (436) -58a
  UC visit 3.34/0 (21) 2.22/0 (16) 1.12
  eD visit 75/0 (225) 107/0 (314) -32
  Office visits 73/0 (118) 89/0 (145) -16
  Antibiotic 90/0 (117) 101/0 (128) -10
  Oral corticosteroid 1.73/0 (3) 2.21/0 (3) -0.48a
Total cost, severe exacerbation  884/0 (2683) 1050/0 (2938) -166
  hospitalization 613/0 (2113) 859/0 (2532) -246
  ICU  271/0 (1813) 191/0 (1526) 80
study medication costs 1651/2002 (643) 962/1307 (501) 689a
Total cost  2778/2024 (2919) 2313/1328 (3224) 465a
Total annualized cost 4291/2101 (11,027) 4596/1469 (13,042) -304a
Notes: aP , 0.05, Wilcoxon rank sum test.
Abbreviations: FSC, fluticasone propionate/salmeterol 250 µg/50 µg; sAL, salmeterol 50 µg; UC, urgent care; er, emergency department; ICU, intensive care unit; COPD, 
chronic obstructive pulmonary disease.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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value from unadjusted costs (Table 4), reflect a similar 
relationship between the two treatment groups.
Discussion
To our knowledge, this is the first economic evaluation 
to use efficacy data from randomized controlled clinical 
trials to estimate cost differences associated with FSC or 
salmeterol therapy for COPD treatment. The pooled clinical 
trial data showed that 87% of patients experienced some 
type of exacerbation, and exacerbation rates were lower in 
patients treated with FSC versus salmeterol. The economic 
evaluation demonstrates corollary cost benefits. On an 
annualized basis, maintenance therapy with FSC incurred 
significantly lower total health care costs than salmeterol, 
with reductions in medical costs more than offsetting the 
higher FSC pharmacy cost. In fact, annualized adjusted 
total pharmacy costs for FSC patients were lower than for 
salmeterol patients. Unadjusted annual total exacerbation and 
therapeutic costs associated with FSC were approximately 
93% of those associated with salmeterol therapy. Predicted 
total costs associated with FSC after adjusting for treatment, 
investigator, COPD reversibility stratum, baseline disease 
severity and time on treatment, were 96% of those associated 
with salmeterol therapy. While cost-effectiveness ratios are 
often calculated in economic evaluations of clinical trials, in 
this case it was not necessary since both exacerbation-related 
medical and pharmacy costs were lower for FSC than for 
salmeterol therapy.
Retrospective studies of health care utilization have 
found that FSC is more cost-effective than ipratropium.9,15,19 
In addition, a cost-benefit study reported lifetime treatment 
with FSC or salmeterol was cost-effective compared to no 
treatment. Earnshaw et al calculated the incremental costs 
of FSC 500/50 therapy to be $33,865 per quality-adjusted-
life-year-gained (QALY), substantially less than the $50,000 
per QALY that is a benchmark against which many public 
health and medical interventions are evaluated.21 Thus, both 
observational approaches and evaluation of actual clinical 
trial data confirm the effectiveness and cost benefit of FSC.
Exacerbation treatment is a large part of the cost of 
treating COPD patients, with ED visits and hospitalizations 
accounting for 70% of all COPD care.22 In this economic 
analysis of clinical trial data, exacerbation costs were a 
lower percentage of costs. Several factors account for this, 
among them, selection bias of clinical trial participants, and 
the higher use of therapeutic medications (and thus higher 
medication costs). Exacerbation costs on an unadjusted basis 
were 64% ($1,262/$2,778) of total analyzed costs for the FSC 
group and 55% ($1,262/$2,313) for the salmeterol group.
Table 5 Mean annual exacerbation rates and relative risks for maintenance therapy with fluticasone propionate/salmeterol versus 
salmeterol therapy
Exacerbation-related event  FSC 
Annualized adjusted 
exacerbation ratesa
SAL 
Annualized adjusted 
exacerbation ratesa
RR, FSC  P-value for RRb
Any exacerbation (mild, moderate, severe) 4.76 5.67 0.84 ,0.001
Moderate/severe exacerbation 1.10 1.58 0.70 ,0.001
Any medical service 1.30 2.11 0.62 ,0.001
  Office visit 1.63 2.15 0.76 ,0.001
  UC/eD visit 0.33 0.43 0.76 0.080
  hospitalization 0.12 0.18 0.69 0.017
Pharmacy
  Antibiotic course 0.93 1.20 0.78 ,0.001
  Oral corticosteroid course 0.74 1.17 0.64 ,0.001
Notes: aMean annual event rate from negative binomial regression models adjusting for treatment, investigator, COPD reversibility stratum, baseline COPD severity and 
time on treatment. bP-value based on χ2 test.
Abbreviations: FSC, fluticasone propionate/salmeterol 250 µg/50 µg; sAL, salmeterol 50 µg; rr, relative risk; UC, urgent care; eD, emergency department; COPD, chronic 
obstructive pulmonary disease.
Table  6  Patients  incurring  exacerbation-related  healthcare 
costs with fluticasone propionate/salmeterol versus salmeterol 
therapya
FSC, N (%) 
(N = 776)
SAL, N (%) 
(N = 778)
Medical services 342 (44.1) 391 (50.3)a
  Office visit 303 (39.0) 338 (43.4)b 
  UC/eD visit 98 (12.6) 104 (13.4)b
  hospitalization 83 (10.7) 99 (12.7)b 
Pharmacy 776 (100) 778 (100)b
Notes: aP , 0.05, χ2 test. bDifferences between groups not significant at 0.05 level, 
χ2 test.
Abbreviations: FSC, fluticasone propionate/salmeterol 250 µg/50 µg; sAL, salme-
terol 50 µg; eD, emergency department; UC, urgent care.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Tied to the large economic burden of exacerbation costs 
are tremendous quality of life issues. As Stanford et al point 
out, failure to prevent or treat acute exacerbations on an out-
patient basis means patients return to the hospital repeatedly 
during their remaining years.7 The Towards a Revolution in 
COPD Health (TORCH) survival study and other studies have 
shown that once an exacerbation occurs there is a decline in 
both lung function and quality of life.5,6 Most recently, the 
Understanding Potential Long-Term Impacts on Function 
with Tiotropium (UPLIFT) study showed that improving 
maintenance therapy results in not just fewer exacerbations 
and hospitalizations, but significantly improved quality of 
life.23 The prevention and treatment of exacerbations is there-
fore a singularly important goal of COPD management and 
a key component of clinical practice guidelines.24,25
Since both cost and quality of life issues are crucial to 
consider when evaluating a therapy’s cost-effectiveness or 
determining a WTP threshold, the lower exacerbation rates and 
lower total health care costs associated with FSC compared to 
salmeterol therapy seen in this study, which occurred despite 
higher FSC drug costs, provide important information for 
decision-makers. This evaluation represents an initial foray 
into evaluating the costs associated with exacerbations and the 
economic benefits associated with a particular drug therapy, and 
further studies are needed to confirm these benefits. Typically, 
when an active treatment has substantial clinical advantages 
over the comparator but comes at a higher drug cost, cost-
  effectiveness (cost-utility) analyses using QALYs are consid-
ered. This provides outcomes in a metric of cost per QALY, or 
cost per exacerbation avoided. In this study, however, FSC was 
associated with significantly lower COPD-related exacerbation 
and therapeutic medical, pharmacy, and total costs compared 
to salmeterol after adjusting and annualizing costs.
This analysis has several advantages. The data used 
were from two year-long, well-controlled RCTs with 
identical protocols and definitions of exacerbations. We 
calculated not only predicted costs for the pooled sample 
(using multivariate regression with a log link and gamma 
distribution), but an adjusted exacerbation rate, lending 
additional rigor to the analysis. In addition, we calculated 
annualized exacerbation rates and costs to account for dif-
ferential study withdrawal and lengths of follow-up. We 
controlled for the possibility that outliers might bias results 
towards one group by considering event-level health care 
utilization rather than person-level. We counted a hospital-
ization as a single event regardless of the length of stay and 
applied a standardized cost figure, since length of stay can 
be affected by additional complications that are unrelated 
to COPD or treatment arm. These methods give the study 
design strong internal validity. To a great extent, biases and 
limitations that routinely exist in the analysis of observa-
tional retrospective studies were avoided in this analysis.
Results from our analyses are only relevant to severe 
COPD patients and for patients using FSC and salmeterol. 
Other COPD medications such as tiotropium were not 
included as therapeutic agents in the trials. A limitation of 
this study is that we did not have access to actual health care 
charges, but assigned proxy unit costs to relevant health care 
utilization events based on cost estimates identified in prior 
research. Thus, the costs reported in this evaluation may 
be higher or lower than actual costs. This is a commonly 
encountered limitation in costing studies, particularly those 
using clinical trial data; however, we do not expect significant 
differences between our estimated costs and actual costs. We 
included protocol-driven office visits in the estimation of 
outpatient costs, and these occurred at a frequency during the 
Table 7 Estimated annual health care costs associated with maintenance therapy with fluticasone propionate/salmeterol versus 
salmeterol
Cost component Mean cost in US dollarsa
FSC group, mean 
(95% CI) 
SAL group, mean 
(95% CI) 
Difference, 
FSC–SAL (95% CIb) 
Medical services  2699 (2612, 2786) 3959 (3820, 4098) -1260 (-1454, -1068)
  Office visit 102 (100, 104) 164 (161, 168) -62 (-67, -57)
  UC/eD visit 179 (174, 185) 317 (307, 327) -138 (-152, -124)
  hospitalization 2492 (2403, 2580) 3455 (3324, 3587) -964 (-1146, -778)
Pharmacy 1972 (1949, 1996) 1316 (1296, 1336) 657 (620, 694)
Total costs 4842 (4731, 4952) 5066 (4937, 5195) -224 (-424, -31)
Notes: aPredicted mean annual costs from gamma regression models (including zero cost observations) adjusting for treatment, investigator, COPD reversibility stratum, 
baseline COPD severity, and time on treatment. bBootstrapped 95% confidence intervals for difference between means.
Abbreviations: FSC, fluticasone propionate/salmeterol 250 µg/50 µg; sAL, salmeterol 50 µg; CI, confidence intervals; COPD, chronic obstructive pulmonary disease.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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clinical trials that may not reflect the usual pattern of care in 
COPD. This may have led to overestimated costs, since fewer 
visits might have occurred if the trial had not taken place. 
This potential overestimation, however, probably affects 
both treatment groups equally. If the effect is unequal, cost 
overestimation is more likely to have occurred in the FSC 
group, since salmeterol patients experienced more exacer-
bations and some protocol-driven office visits would have 
substituted for visits that would have occurred if the trial 
had not taken place.
Conclusion
Compared to salmeterol monotherapy, FSC combination 
therapy provides significant clinical benefit through a 
reduction in exacerbations. This benefit is achieved at 
a relatively small additional drug cost and an overall 
savings in total COPD-related exacerbation and therapeutic 
health care costs. Because there is substantial room for 
improvement in the current management of COPD patients, 
the cost-benefit information provided by this analysis may 
be beneficial in evaluating COPD maintenance therapies 
against willingness-to-pay thresholds. Given the large impact 
of COPD exacerbations on patient quality of life, lung 
function, and the subsequent course of the disease, optimizing 
maintenance therapy in patients with severe COPD could 
have a large impact on patients’ lives. Conversely, suboptimal 
management may not only adversely affect clinical outcomes, 
but increase the cost of care.
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